MED12 Antibody

中文名稱：

MED12兔多克隆抗體
貨號：

CSB-PA853101LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human brain tissue using CSB-PA853101LA01HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human gastric cancer using CSB-PA853101LA01HU at dilution of 1:100
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) MED12 Polyclonal antibody
Uniprot No.：

Q93074
基因名：

MED12
別名：

Activator recruited cofactor 240 kDa component antibody; Activator-recruited cofactor 240 kDa component antibody; ARC240 antibody; CAG repeat protein 45 antibody; CAGH45 antibody; HOPA antibody; KIAA0192 antibody; MED12 antibody; MED12_HUMAN antibody; Mediator complex subunit 12 antibody; Mediator of RNA polymerase II transcription subunit 12 antibody; OPA containing protein antibody; OPA-containing protein antibody; Thyroid hormone receptor associated protein complex 230 kDa component antibody; Thyroid hormone receptor-associated protein complex 230 kDa component antibody; TNRC11 antibody; Trap230 antibody; Trinucleotide repeat containing gene 11 protein antibody; Trinucleotide repeat-containing gene 11 protein antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Mediator of RNA polymerase II transcription subunit 12 protein (1742-2011AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產(chǎn)品，MED12 Antibody (CSB-PA853101LA01HU)，的標記方式是Non-conjugated。對于MED12 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA853101LB01HU	MED12 Antibody, HRP conjugated	ELISA
FITC	CSB-PA853101LC01HU	MED12 Antibody, FITC conjugated
Biotin	CSB-PA853101LD01HU	MED12 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signaling pathway and SHH signaling pathway.
基因功能參考文獻：
1. we aimed in this study to examine these common functional pathways in uterine leiomyomas (ULM)with different driver mutations. We collected ULM with MED12, HMGA2, and FH mutations and examined the selected markers by immunohistochemistry. PMID: 29790226
2. Here, we observed that overexpression of HMGA2 mRNA in tumors measured by quantitative PCR and compared to myometrium is a common phenomenon in fibroids and is frequently associated with MED12 mutations. In addition, the common clonal origin of tumors overexpressing HMGA2 mRNA and its expression in few myometrial tissue points to HMGA2 up-regulation as an early event in leiomyoma tumorigenesis. PMID: 30017537
3. Study confirmed the association of MED12 mutations with smaller leiomyoma size, multiplicity and conventional hystotype, and revealed novel associations between the MED12-mutation status and leiomyoma location and parity. PMID: 28432313
4. High frequency of the MED12 mutation in uterine leiomyomas of South Korean patients. PMID: 29333096
5. The high rate of TERT promoter mutations, MED12 mutations, RBM10 mutations, and chromosome 1q gain highlight their likely association with tumor virulence PMID: 28634282
6. Role of MED12 as a tumor suppressor in other cancers to include CRC, and suggest TGF-beta signaling as a potential mediator of this effect. PMID: 28183795
7. Hormonal status changing at various phases of menstrual cycle is a factor affecting DNA hydroxymethylation in leiomyoma cells. PMID: 28944423
8. High MED12 expression is associated with small cell lung cancer. PMID: 28055980
9. Data indicate that mediator complex subunit 12 (MED12) plays a central oncogenic role in breast fibroepithelial tumorigenesis. PMID: 27806318
10. MED12 mutation does not appear to represent a significant molecular alteration in this cohort of patients according to the analysis by the traditional "gold standard." PMID: 26924278
11. knockdown of MED12 was shown to confer resistance to apoptosis following pediatric T-cell acute lymphoblastic leukemia relevant chemotherapy drug treatment in Jurkat leukemia cells PMID: 27602765
12. Our findings provide new mechanistic insights into the MED12 functions and indicate that somatic nonsense mutations in early exons may avoid NMD. PMID: 28054750
13. With a strong genotype-phenotype correlation that is already known for MED12, this could be a new phenotype linked to MED12, thus expanding the phenotypic spectrum of MED12-related disorders. PMID: 28544239
14. The results suggest that MED12 mutations may contribute to chronic lymphocytic leukaemia pathogenesis by activating NOTCH signalling. PMID: 28771672
15. we investigated several MED12 patients mutations (p.R206Q, p.N898D, p.R961W, p.N1007S, p.R1148H, p.S1165P and p.R1295H) and show that each MED12 mutations cause specific expression patterns of JUN, FOS and EGR1 immediate early genes (IEGs), reflected by the presence or absence of MED12 containing complex at their respective promoters. PMID: 28369444
16. MED12 variants identified in males need to be evaluated carefully for these characteristics, as this severe phenotype may predict a potential risk for phenotypic expression in the heterozygotes. The identification of such a phenotype could influence the interpretation of future whole exome sequencing data and thus genetic counseling. PMID: 27312080
17. Current study findings may help to narrow down the number of MED12 mutations to be screened for mediator complex dysfunction associated genetic diseases. This study supports computational methods as a primary filter to verify the plausible impact of pathogenic mutations based on the perspective of evolution, expression and phenotype of proteins. PMID: 26813965
18. MED12-mutated adenosarcoma-like tumours might represent a distinct entity that requires more studies for its identification. MED12 exon 2 mutations seemed to have no significant role in other uncommon gynaecological mesenchymal tumours. PMID: 28002623
19. role in the regulation of uterine fibroid cell proliferation through the modulation of Wnt/beta-catenin, cell cycle-associated, and fibrosis-associated protein expression PMID: 27967206
20. Somatic MED12 mutations and biallelic FH inactivation are mutually exclusive in both HLRCC syndrome-associated and sporadic uterine leiomyomas. The great majority of HLRCC patients' uterine leiomyomas are caused by FH inactivation, but incidental tumours driven by somatic MED12 mutations also occur. PMID: 27187686
21. 4.6% of leiomyosarcomas harbored MED12 exon 2 mutations, but the relevance of this association with molecular pathogenesis of leiomyosarcoma remains unknown. PMID: 27889101
22. The high frequency and similar patterns of MED12 mutations in fibroadenomas and various grades of phyllodes tumours implies that the MED12 mutation is a common and early pathological event in these fibroepithelial tumours. PMID: 26109290
23. Positive associations observed between MED12 and ERalpha, ERbeta immunohistochemical expression suggest a biological interplay between the proteins. PMID: 27056456
24. increased MED12 exon 2 mutation frequency in the multiple Uterine Leiomyomas was not accompanied by significant alterations in the spectrum of mutation categories PMID: 26630226
25. Patients with malignant PTs that harbored MED12 mutations demonstrated improved disease-free survival (DFS) compared with those without MED12 mutation PMID: 26856273
26. MED12 mutations are associated with fibroid pathogenesis in a series of 103 uterine leiomyomas samples PMID: 26298726
27. The biological function of MED12 and the relationship between MED12 mutations and diseases. Review. PMID: 23836153
28. MED12 gene mutation is associated with Lujan-Fryns syndrome. PMID: 26358559
29. Missense mutation in the MED12 gene is associated with hypertonia, eosinophilic esophagitis, penile chordee, and particular facial dysmorphisms beyond Ohdo syndrome. PMID: 26338144
30. In conclusion, the authors demonstrated the restriction of MED12 exon 2 mutation to phyllodes tumours (73.6%, 39/53) and its absence in other spindle neoplasms of the breast. PMID: 26860948
31. our results suggest that the majority of malignant breast phyllodes tumours may be driven by genetic/epigenetic alterations other than MED12 exon 2 somatic mutations PMID: 25855048
32. Data suggest that MED13, MED12, CDK8 and cyclin C (CycC) comprise a four-subunit "kinase" module of the Mediator complex that functions as a major ingress of oncogenic and developmental signaling/gene expression in humans. [REVIEW] PMID: 26182352
33. Frequent MED12 mutations in uterine leiomyosarcomas PMID: 26891131
34. Specific somatic MED12 mutations in prostate cancer and uterine leiomyomas accumulate in two separate regions of the gene and promote tumorigenesis through clearly distinct mechanisms. PMID: 26383637
35. This revealed four patients to have two or more tumors that were clonally related, all of which lacked MED12 mutations. DEPDC5 was discovered as a novel tumor suppressor gene playing a role in the progression of uterine leiomyomas. PMID: 25964426
36. Frequent mutations in MED12 exon 2 in the phyllodes tumors suggest that it may share genetic etiology with uterine leiomyoma, a subgroup of uterine leiomyosarcomas and breast fibroadenoma. PMID: 25865354
37. the MED12 mutation is implicated in the pathogenesis of both FA and PT and that a certain percentage of FAs with MED12 mutation may progress to PTs. PMID: 26093648
38. MED12 mutations were closely associated with the development of uterine leiomyomas, as opposed to other uterine pathologies in Chinese patients, and PCR-based HRMA was found to be a reliable method for the detection of MED12 mutations. PMID: 25615570
39. Results demonstrate frequent MED12 mutations in phyllodes tumors, supporting a shared origin with benign breast fibroadenomas. PMID: 25593300
40. The results show frequent occurrence of MED12 mutations in fibroadenomas, intracanalicular fibroadenomas closely resemble benign phyllodes, benign phyllodes tumors harbor MED12 mutations, MED12 mutations in malignant phyllodes tumors are relatively rare. PMID: 25931199
41. A critical role of TERT promoter mutations, in cooperation with MED12 mutations, in the development of phyllodes tumors. PMID: 26355235
42. Additional studies on the role of MED12 mutation status as a putative prognostic factor as well as mutations' exact tumorigenic mechanism in CLL are warranted. PMID: 25595892
43. Similar to fibroadenomas, breast phyllodes tumours show a high frequency of MED12 mutations, affirming the close biological relationship between these fibroepithelial neoplasms PMID: 26018969
44. leiomyomatous, Med12 c.131G>A variant-expressing uteri developed chromosomal rearrangements. PMID: 26193636
45. the relationship between MED12 mutations and uterine leiomyosarcoma and the lack of expression (by western blot or IHC) in most leiomyosarcoma is not correlated with mutational status. PMID: 26037152
46. MED12 mutations were confined to the stromal components in both phyllodes tumours. PMID: 25839987
47. Uterine leiomyoma (UL) pseudocapsules always showed a wild type MED12 gene status, even when associated with a UL harboring a specific MED12 aberration PMID: 25363374
48. Mutational analysis of the MED12 gene revealed that leiomyomas exhibited mutations in the MED12 gene PMID: 25015674
49. The MED12 gene exon 2 is frequently mutated in human uterine fibroids in Southern United States women. PMID: 25325994
50. These results further emphasize the role of MED12 in uterine leiomyomas, show that exon 1 and exon 2 exert their tumorigenic effect in similar manner, and stress that exon 1 should be included in subsequent MED12 screenings. PMID: 24980722
顯示更多

收起更多
相關(guān)疾病：

Opitz-Kaveggia syndrome (OKS); Lujan-Fryns syndrome (LUJFRYS); Ohdo syndrome, X-linked (OHDOX)
亞細胞定位：

Nucleus.
蛋白家族：

Mediator complex subunit 12 family
組織特異性：

Ubiquitous.
數(shù)據(jù)庫鏈接：

HGNC: 11957

OMIM: 300188

KEGG: hsa:9968

STRING: 9606.ENSP00000363193

UniGene: Hs.409226

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human